問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳蓉宣
下載
2025-03-01 - 2032-01-31
Condition/Disease
Compare the efficacy of T-DXd plus bevacizumab (Group A) versus bevacizumab monotherapy (Group B) in the HER2 IHC 3+/2+ population, as assessed by BICR for progression-free survival (PFS).
Test Drug
Trastuzumab Deruxtecan (T-DXd、DS-8201a)
Participate Sites7Sites
Recruiting7Sites
2025-04-01 - 2032-12-31
Progression-free survival (PFS): Time from randomization to the first recorded disease progression or death from any cause, whichever occurs first. Overall survival (OS): Time from randomization to death from any cause.
Pembrolizumab (MK-3475) Sacituzumab Tirumotecan (MK-2870)
Participate Sites5Sites
Recruiting5Sites
2022-10-01 - 2030-05-31
2022-06-01 - 2029-09-30
Participate Sites3Sites
Recruiting3Sites
2025-11-19 - 2030-06-30
Participate Sites10Sites
Recruiting10Sites
2020-12-25 - 2026-12-31
2021-10-01 - 2027-12-31
Participate Sites8Sites
Recruiting8Sites
2025-03-01 - 2030-03-31
Participate Sites6Sites
Recruiting6Sites
2021-07-30 - 2025-12-31
Participate Sites4Sites
Recruiting4Sites
2021-03-17 - 2028-12-31
全部
